{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:57:22Z","timestamp":1790805442471,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62175031"],"award-info":[{"award-number":["62175031"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014125","name":"Fujian Provincial Health Commission","doi-asserted-by":"publisher","award":["2021ZQNZD013"],"award-info":[{"award-number":["2021ZQNZD013"]}],"id":[{"id":"10.13039\/501100014125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fundamental Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.fmre.2025.04.015","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T02:47:14Z","timestamp":1747190834000},"page":"3417-3430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic delivery of stealth adenoviral vector to reinvigorate antitumor immunity by PD-L1 genome editing and TIGIT\/CD155 blocking"],"prefix":"10.1016","volume":"6","author":[{"given":"Ming","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoxue","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7939-2654","authenticated-orcid":false,"given":"Youshi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3096-4981","authenticated-orcid":false,"given":"Xiaolong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fmre.2025.04.015_bib0001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.fmre.2025.04.015_bib0002","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.fmre.2025.04.015_bib0003","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Dranoff, biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.fmre.2025.04.015_bib0004","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.fmre.2025.04.015_bib0005","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1158\/1078-0432.CCR-19-3925","article-title":"Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma","volume":"26","author":"Lepletier","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.fmre.2025.04.015_bib0006","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Ramalingam, Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.fmre.2025.04.015_bib0007","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.fmre.2025.04.015_bib0008","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature23643","article-title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","volume":"549","author":"Burr","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.fmre.2025.04.015_bib0009","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","article-title":"Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours","volume":"3","author":"Yao","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.fmre.2025.04.015_bib0010","article-title":"Reprogramming the tumor microenvironment through second-near-infrared-window photothermal genome editing of PD-L1 mediated by supramolecular gold nanorods for enhanced cancer immunotherapy","volume":"33","author":"Tang","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.fmre.2025.04.015_bib0011","article-title":"Silk-gel powered adenoviral vector enables robust genome editing of PD-L1 to augment immunotherapy across multiple tumor models","volume":"10","author":"Wu","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.fmre.2025.04.015_bib0012","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jconrel.2020.09.003","article-title":"Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors","volume":"327","author":"Boucher","year":"2020","journal-title":"J. Control. Release."},{"key":"10.1016\/j.fmre.2025.04.015_bib0013","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymthe.2016.12.006","article-title":"CRISPR\/Cas9-mediated genome editing as a therapeutic approach for leber congenital amaurosis 10","volume":"25","author":"Ruan","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.fmre.2025.04.015_bib0014","doi-asserted-by":"crossref","first-page":"eabc6659","DOI":"10.1126\/scitranslmed.abc6659","article-title":"Systemic cancer therapy with engineered adenovirus that evades innate immunity","volume":"12","author":"Atasheva","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.fmre.2025.04.015_bib0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/17425247.2016.1158707","article-title":"Redirecting adenovirus tropism by genetic, chemical, and mechanical modification of the adenovirus surface for cancer gene therapy","volume":"13","author":"Yoon","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.fmre.2025.04.015_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201706759","article-title":"Cell membrane coating nanotechnology","volume":"30","author":"Fang","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.fmre.2025.04.015_bib0017","first-page":"57","article-title":"Red blood cell-mimic nanocatalyst triggering radical storm to augment cancer immunotherapy","volume":"14","author":"Li","year":"2022","journal-title":"Nanomicro Lett."},{"key":"10.1016\/j.fmre.2025.04.015_bib0018","article-title":"Biodegradable MnO2-based gene-engineered nanocomposites for chemodynamic therapy and enhanced antitumor immunity","volume":"18","author":"Wang","year":"2023","journal-title":"Mater. Today Bio."},{"key":"10.1016\/j.fmre.2025.04.015_bib0019","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.1038\/s41467-019-13744-8","article-title":"Artificially cloaked viral nanovaccine for cancer immunotherapy","volume":"10","author":"Fusciello","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.fmre.2025.04.015_bib0020","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/acs.nanolett.9b00145","article-title":"Genetically engineered cell membrane nanovesicles for oncolytic adenovirus delivery: a versatile platform for cancer virotherapy","volume":"19","author":"Lv","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.fmre.2025.04.015_bib0021","article-title":"Genetically engineered liposome-like nanovesicles as active targeted transport platform","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.fmre.2025.04.015_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101341","article-title":"Converting immune cold into hot by biosynthetic functional vesicles to boost systematic antitumor immunity","volume":"23","author":"Wu","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.fmre.2025.04.015_bib0023","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12951-022-01266-3","article-title":"Functional nanovesicles displaying anti-PD-L1 antibodies for programmed photoimmunotherapy","volume":"20","author":"Chen","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.fmre.2025.04.015_bib0024","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41565-022-01098-0","article-title":"A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy","volume":"17","author":"Liu","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.fmre.2025.04.015_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mellman, mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.fmre.2025.04.015_bib0026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4236\/alc.2022.114005","article-title":"Targeting TIGIT in NSCLC\u2014Is there light on the horizon?","volume":"11","author":"Reuther","year":"2022","journal-title":"Adv. Lung Cancer"},{"key":"10.1016\/j.fmre.2025.04.015_bib0027","doi-asserted-by":"crossref","first-page":"26320","DOI":"10.1002\/anie.202108342","article-title":"Genetically programmable fusion cellular vesicles for cancer immunotherapy","volume":"60","author":"Meng","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.fmre.2025.04.015_bib0028","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/138920110791111960","article-title":"Cell engineering and cultivation of Chinese hamster ovary (CHO) cells","volume":"11","author":"Omasa","year":"2010","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.fmre.2025.04.015_bib0029","article-title":"PD-1 blockade cellular vesicles for cancer immunotherapy","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.fmre.2025.04.015_bib0030","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3892\/or.2021.7943","article-title":"CD155\/TIGIT, a novel immune checkpoint in human cancers","volume":"45","author":"Liu","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.fmre.2025.04.015_bib0031","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1134\/S0026893319060116","article-title":"Methods of evaluating the efficiency of CRISPR\/Cas genome editing","volume":"53","author":"Lomov","year":"2019","journal-title":"Mol. Biol."},{"key":"10.1016\/j.fmre.2025.04.015_bib0032","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.fmre.2025.04.015_bib0033","doi-asserted-by":"crossref","first-page":"11031","DOI":"10.1128\/JVI.00783-12","article-title":"Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques","volume":"86","author":"Sun","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.fmre.2025.04.015_bib0034","doi-asserted-by":"crossref","first-page":"0016","DOI":"10.34133\/bmef.0016","article-title":"Principles of nanoparticle delivery to solid tumors","volume":"4","author":"Chan","year":"2023","journal-title":"BME Front."},{"key":"10.1016\/j.fmre.2025.04.015_bib0035","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41565-021-00972-7","article-title":"T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy","volume":"16","author":"Zhai","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.fmre.2025.04.015_bib0036","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","article-title":"Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo","volume":"350","author":"Zhou","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.fmre.2025.04.015_bib0037","article-title":"Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through toll-like receptor 4 signaling","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.fmre.2025.04.015_bib0038","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2020.38.15_suppl.9503","article-title":"Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1l) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)","volume":"38","author":"Rodriguez-Abreu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.fmre.2025.04.015_bib0039","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"Grogan, the immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.fmre.2025.04.015_bib0040","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1021\/acs.nanolett.8b02321","article-title":"Engineering PD-1-presenting platelets for cancer immunotherapy","volume":"18","author":"Zhang","year":"2018","journal-title":"Nano Lett."}],"container-title":["Fundamental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667325825002201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667325825002201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:08:29Z","timestamp":1790802509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667325825002201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2667325825002201"],"URL":"https:\/\/doi.org\/10.1016\/j.fmre.2025.04.015","relation":{},"ISSN":["2667-3258"],"issn-type":[{"value":"2667-3258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic delivery of stealth adenoviral vector to reinvigorate antitumor immunity by PD-L1 genome editing and TIGIT\/CD155 blocking","name":"articletitle","label":"Article Title"},{"value":"Fundamental Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fmre.2025.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}